Novel Compounds offer hope in $22 Billion Fight Against Bovine Mastitis
Table of Contents
A breakthrough finding by researchers offers a promising choice to antibiotics in combating bovine mastitis, a widespread and costly bacterial infection affecting dairy cows globally.The new approach,detailed in a recent study,could significantly reduce annual losses estimated at US$22 billion (S$28 billion) and address growing concerns surrounding antibiotic resistance and milk contamination.
The Growing Crisis of Bovine Mastitis
For decades, the dairy industry has struggled with bovine mastitis, an infection of the cow udder that dramatically reduces milk production. Customary treatment relies heavily on antibiotics, but this practice is increasingly problematic. Rising antibiotic resistance threatens the effectiveness of these treatments, while concerns persist about antibiotic residues contaminating milk supplies.
“The reliance on antibiotics has created a critical need for alternative solutions,” stated a senior official familiar with the research.
A New Mechanism of Action: Oligoimidazolium Carbon Acids (OIMs)
An international team led by Nanyang Technological University, Singapore (NTU Singapore) and the Singapore MIT Alliance for Research and Technology (SMART) has developed a novel class of antimicrobial compounds called oligoimidazolium carbon acids (OIMs). These compounds work by disrupting the bacterial cell membrane, effectively killing the bacteria without relying on the mechanisms targeted by traditional antibiotics.
In laboratory tests, OIMs demonstrated potent activity against a wide range of bacteria commonly associated with mastitis, including multi-drug-resistant strains. Crucially, the compounds were tested on dairy cows and successfully staved off infection even after exposure to bacteria. Importantly, the OIMs did not cause irritation or adverse effects in the cattle tested.
“Our study has unveiled an alternative class of potent antimicrobial compounds that could be used in the agriculture industry to combat multi-drug-resistant bacteria,” explained Professor Mary Chan, a co-lead researcher from NTU Singapore and SMART AMR. “The compounds did not spoil the cows’ milk nor make it unsafe for consumption.”
Industry Interest and Commercialization Plans
The innovative compounds have already attracted significant interest from agricultural companies in Australia, Belgium, Malaysia, and New Zealand. These businesses are actively seeking safer and more environmentally pleasant alternatives to existing teat disinfectants like iodine and chlorhexidine.
Professor Paula Hammond, from MIT and SMART AMR, noted, “With the success of our initial study in both the laboratory and in the field, we are now planning to work closely with industry partners to scale up and do larger trials in dairy cattle, with the aim of commercialising the novel antimicrobial compounds.”
A larger farm trial is currently underway in Malacca, Malaysia, to further optimize the OIMs. The research team is also establishing a spin-off company to facilitate commercialization.
Addressing Environmental Concerns
Current methods of teat disinfection, utilizing iodine and chlorhexidine, pose environmental risks. Long-term use can irritate udders and lead to skin cracking, increasing infection risk. Moreover, these disinfectants can disrupt the nutrient balance in nature and harm aquatic life. OIMs offer a lasting advantage, as they are biodegradable and break down into non-toxic, non-polluting molecules.
“The OIMs are biodegradable and break down into natural molecules that are neither toxic nor polluting, so we expect them to be more environmentally friendly than using iodine or chlorhexidine,” explained Dr. Kaixi Zhang, a co-author of the study. unlike traditional disinfectants, the OIMs’ antibacterial properties are also unaffected by the presence of milk.
Future Applications Beyond Dairy
The potential of OIMs extends beyond dairy farming. Researchers found the compounds effectively killed multi-drug-resistant bacteria in mice without causing significant harm, opening doors for future progress in the biomedical field.
“This opens the way for the compounds to be further developed and optimised for other therapeutic applications in the biomedical field in the future,” saeid Professor Kevin pethe, the study’s other co-lead from NTU.
The development of OIMs represents a significant step forward in the fight against antibiotic resistance and offers a sustainable solution to a long-standing problem in the dairy industry, promising a healthier future for both cows and consumers.
